Piscura M, Henderson-Redmond A, Barnes R, Mitra S, Guindon J, Morgan D
Biochem Pharmacol. 2023; 214:115665.
PMID: 37348821
PMC: 10528043.
DOI: 10.1016/j.bcp.2023.115665.
Aychman M, Goldman D, Kaplan J
Front Neurol. 2023; 14:1087011.
PMID: 36816569
PMC: 9932048.
DOI: 10.3389/fneur.2023.1087011.
Henderson-Redmond A, Crawford L, Sepulveda D, Hale D, Lesperance J, Morgan D
Front Mol Biosci. 2021; 8:684115.
PMID: 34250019
PMC: 8267820.
DOI: 10.3389/fmolb.2021.684115.
Kesner A, Lovinger D
J Neurochem. 2021; 157(5):1674-1696.
PMID: 33891706
PMC: 9291571.
DOI: 10.1111/jnc.15369.
Filip R, Desrochers G, Lefebvre D, Reed A, Singaravelu R, Cravatt B
Cell Chem Biol. 2021; 28(2):202-212.e6.
PMID: 33450181
PMC: 8323987.
DOI: 10.1016/j.chembiol.2020.12.009.
Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.
Nealon C, Henderson-Redmond A, Hale D, Morgan D
Neuropharmacology. 2019; 148:151-159.
PMID: 30629988
PMC: 6535342.
DOI: 10.1016/j.neuropharm.2018.12.026.
Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.
Mulpuri Y, Marty V, Munier J, Mackie K, Schmidt B, Seltzman H
Neuropharmacology. 2018; 139:85-97.
PMID: 29981335
PMC: 6883926.
DOI: 10.1016/j.neuropharm.2018.07.002.
Δ-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal Cortex.
Lazenka M, Kang M, De D, Selley D, Sim-Selley L
Cannabis Cannabinoid Res. 2017; 2(1):224-234.
PMID: 29082320
PMC: 5628572.
DOI: 10.1089/can.2017.0022.
Cannabinoid Hyperemesis Syndrome: A Case Report of Cyclic Severe Hyperemesis and Abdominal Pain with Long-Term Cannabis Use.
Hermes-Laufer J, Del Puppo L, Inan I, Troillet F, Kherad O
Case Rep Gastrointest Med. 2016; 2016:2815901.
PMID: 27980870
PMC: 5131230.
DOI: 10.1155/2016/2815901.
Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms.
Darmani N
Pharmaceuticals (Basel). 2016; 3(7):2163-2177.
PMID: 27713347
PMC: 4036650.
DOI: 10.3390/ph3072163.
Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.
Grim T, Samano K, Ignatowska-Jankowska B, Tao Q, Sim-Selly L, Selley D
J Basic Clin Physiol Pharmacol. 2016; 27(3):217-28.
PMID: 27149200
PMC: 5644386.
DOI: 10.1515/jbcpp-2015-0118.
Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M, Bindila L, Lutz B, Zimmer A, Bilkei-Gorzo A, Schlicker E
Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(6):603-12.
PMID: 26984820
DOI: 10.1007/s00210-016-1226-6.
Enhanced Glutamatergic Synaptic Plasticity in the Hippocampal CA1 Field of Food-Restricted Rats: Involvement of CB1 Receptors.
Talani G, Licheri V, Biggio F, Locci V, Mostallino M, Secci P
Neuropsychopharmacology. 2015; 41(5):1308-18.
PMID: 26354043
PMC: 4793114.
DOI: 10.1038/npp.2015.280.
Cannabinoids and Epilepsy.
Rosenberg E, Tsien R, Whalley B, Devinsky O
Neurotherapeutics. 2015; 12(4):747-68.
PMID: 26282273
PMC: 4604191.
DOI: 10.1007/s13311-015-0375-5.
CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L, Cornett B, Mackie K, Hohmann A
Mol Pharmacol. 2015; 88(1):64-74.
PMID: 25904556
PMC: 4468646.
DOI: 10.1124/mol.115.098483.
Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice.
Morgan D, Davis B, Kearn C, Marcus D, Cook A, Wager-Miller J
J Neurosci. 2014; 34(15):5152-63.
PMID: 24719095
PMC: 3983798.
DOI: 10.1523/JNEUROSCI.3445-12.2014.
Chronic administration during early adulthood does not alter the hormonally-dependent disruptive effects of delta-9-tetrahydrocannabinol (Δ9-THC) on complex behavior in female rats.
Winsauer P, Sutton J
Pharmacol Biochem Behav. 2013; 117:118-27.
PMID: 24361784
PMC: 3957192.
DOI: 10.1016/j.pbb.2013.12.014.
Dissociation of the pharmacological effects of THC by mTOR blockade.
Puighermanal E, Busquets-Garcia A, Gomis-Gonzalez M, Marsicano G, Maldonado R, Ozaita A
Neuropsychopharmacology. 2013; 38(7):1334-43.
PMID: 23358238
PMC: 3656376.
DOI: 10.1038/npp.2013.31.
Brain CB₁ receptor expression following lipopolysaccharide-induced inflammation.
Hu H, Ho W, Mackie K, Pittman Q, Sharkey K
Neuroscience. 2012; 227:211-22.
PMID: 23041513
PMC: 3505253.
DOI: 10.1016/j.neuroscience.2012.09.067.
Brain regional differences in CB1 receptor adaptation and regulation of transcription.
Lazenka M, Selley D, Sim-Selley L
Life Sci. 2012; 92(8-9):446-52.
PMID: 22940268
PMC: 3772765.
DOI: 10.1016/j.lfs.2012.08.023.